Company profile
Ainos, Inc.
NASDAQ: AIMD · Healthcare · Biotechnology
#1029 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
41DFH 27DQ 63GM 37SS 40
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), disclosure history · ↓ growth stability, operating margin
Methodology →Revenue TTM
$13.6k
Rev growth YoY (TTM)
-87.7%
Net income (FY)
-$14.8M
Employees
41
as of 2026-08-23
Market cap
$10.5M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$124.2k$124.2k2025
Net income-$14.8M-$14.8M2025
Operating income-$14.0M-$14.0M2025
Total assets$20.9M$20.9M2025
Liabilities$13.3M$13.3M2025
Equity$7.6M$7.6M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Ainos, Inc.’s revenue?
Ainos, Inc. booked $124.2k in FY2025 revenue, growing 499% year over year — faster than 94% of Healthcare companies we track, at a -11897.0% net margin.
Peers · Healthcare
VentriPoint Diagnostics Ltd.31DPanamera Holdings Corporation31DCandel Therapeutics, Inc.33DAdvanced BioMedical Technologies Inc.——AI/ML Innovations Inc.——Viracta Therapeutics, Inc.——Neighbors
San Diego →Key facts
CEOChun-Hsien Tsai
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: AIMD
Employees41
IPO date2021-01-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.